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The clinical use of the antitumor anthracycline Doxorubicin is limited by the risk of
severe cardiotoxicity. The mechanisms underlying anthracycline-dependent cardiotoxicity
are multiple and remain uncompletely understood, but many observations indicate that
interactions with cellular iron metabolism are important. Convincing evidence showing
that iron plays a role in Doxorubicin cardiotoxicity is provided by the protecting efﬁcacy
of iron chelation in patients and experimental models, and studies showing that iron
overload exacerbates the cardiotoxic effects of the drug, but the underlying molecular
mechanisms remain to be completely characterized. Since anthracyclines generate reactive
oxygen species, increased iron-catalyzed formation of free radicals appears an obvious
explanation for the aggravating role of iron in Doxorubicin cardiotoxicity, but antioxidants
did not offer protection in clinical settings. Moreover, how the interaction between reactive
oxygen species and iron damages heart cells exposed to Doxorubicin is still unclear. This
review discusses the pathogenic role of the disruption of iron homeostasis in Doxorubicin-
mediated cardiotoxicity in the context of current and future pharmacologic approaches to
cardioprotection.
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INTRODUCTION
Doxorubicin (DOX) is awidely used anthracycline anticancer drug
that intercalates in DNA and inhibits topoisomerase II. More than
four decades after discovery, DOX still ranks among the most
effective agents in breast cancer and numerous other neoplas-
tic diseases. Unfortunately, the clinical use of DOX is limited by
the possible development of cardiomyopathy and congestive heart
failure (CHF). The various forms of anthracycline-mediated car-
diotoxicity, as well as the reasons for the particular susceptibility of
cardiac cells, have been reviewed elsewhere (Minotti et al., 2004a;
Berthiaume and Wallace, 2007; Octavia et al., 2012; Carvalho
et al., 2014); here we will summarize the major clinical conse-
quences of this toxicity, and then review the biochemical mech-
anisms of anthracycline cardiotoxicity, focusing on the role of
iron.
Since a tight relationship between the quantity of DOX accu-
mulated in the heart and the incidence of cardiac events has
been identiﬁed, the lifetime cumulative dose of DOX usually
does not exceed 500 mg/m2; this reduces considerably the inci-
dence of treatment-requiring cardiac events, but sometimes can
preclude successful completion of chemotherapy. Moreover, car-
diomyopathy may develop at lower doses in the presence of risk
factors like age, hypertension, arrhythmias, coronary disease, etc.
(Gianni et al., 2008). Therefore, the dose-adjusted chance of car-
diotoxicity may be more elevated than expected, and the necessity
to adjust doses limits the therapeutic capability of DOX and
other anthracyclines. It should also be considered that anthracy-
cline cardiotoxicity is often exacerbated by combination therapies
involving classic drugs like taxanes or new drugs targeting growth
factor receptors or signal transducing molecules activated in
tumors (Gianni et al., 2008).
Since at present there is no speciﬁc and effective pharma-
cological treatment for DOX-related cardiomyopathy, cardiac
transplantation often remains the only option for patients with
DOX-dependent advanced cardiomyopathy and CHF. It is there-
fore evident that the risk of developing cardiac events because of
anthracycline treatment is a life-threatening problem for a high
number of cancer survivors. In particular, given the peculiar
delay in the appearance of toxic consequences, which may become
manifest several years after completing chemotherapy (Minotti
et al., 2004a), DOX cardiotoxicity represents a serious problem in
pediatric oncology (Lipshultz et al., 2013a).
Despite convincing evidence linking the levels of DOX in the
heart and the development of cardiomyopathy, the precise mecha-
nisms through which DOX eventually induces cardiac damage are
much less clear; this uncertainty is also dependent on obstacles to
investigation posed by species-related differences in anthracycline
metabolism and susceptibility to DOX-derived reactive oxygen
species (ROS; see below), as well as to inherent difﬁculties in devel-
oping animal models reliably recapitulating chronic and delayed
cardiotoxicity.
Anthracycline-induced cardiotoxicity is amultifactorial process
based on mechanisms only in part distinct from those targeting
cancer cells. In fact, it has been demonstrated that the interaction
of DOX with topoisomerase, which is key for the antitumor effect
of anthracyclines, is also relevant for cardiotoxicity (Zhang et al.,
2012). Other mechanisms include suppression of the cardiac-
speciﬁc gene expression program, persistent alterations of calcium
compartmentalization, changes in adrenergic function, inhibition
of the expression of several sarcomeric proteins, promotion of free
radical reactions beyond the limited antioxidant defence of car-
diomyocytes that eventually lead to lipid peroxidation (Minotti
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et al., 2004a). Great attention is paid to the latter mechanism
because a number of studies have shown that reductive activa-
tion of the quinone moiety of DOX (Figure 1) by a number
of reductases, including the reductase domain of endothelial
nitric oxide synthase (Fogli et al., 2004), eventually results in the
formation of superoxide anion (O2•−) and hydrogen peroxide
(H2O2) that may cause oxidative stress and cell injury in car-
diomyocytes (Minotti et al., 2004b; Berthiaume andWallace, 2007;
Octavia et al., 2012; Steˇrba et al., 2013; Carvalho et al., 2014). In
this context, the role of ROS-generating mitochondrial quinone
reductases appears particularly relevant, as also indicated by the
abundance of mitochondria in the heart. In addition to bio-
chemical evidence, the role of ROS produced by the reductases
was underlined by studies in genetically modiﬁed mice showing
a relation between cardiotoxicity and either deletion of enzymes
involved in anthracycline metabolism or overexpression of antiox-
idant proteins (reviewed in Minotti et al., 2004a). Interestingly, a
high-risk variant of a gene involved in free radical generation sig-
niﬁcantly increased the susceptibility to DOX-dependent CHF in
survivors of hematopoietic cell transplantation (Armenian et al.,
2013).
Other pathways of DOX metabolism are also highly relevant for
cardiotoxicity. Reductionof the carbonyl group in ringA to alcohol
(Figure 1) changes DOX into DOXol that, being more polar than
DOX,accumulates at higher levels and for longer times in theheart,
thus helping to understand chronic cardiotoxicity. Moreover, it has
been shown that DOXol is remarkably more potent than its par-
ent molecule at dysregulating iron homeostasis (see below). The
role of DOXol in cardiotoxicity is reinforced by studies showing
correlation between polymorphisms in the genes coding for car-
bonyl reductases that form DOXol and cardiovascular morbidity
(Blanco et al., 2008).
However, in addition to the reductive metabolism described
above, DOX can undergo oxidative degradation catalyzed by
peroxidases. Recent elegant studies identiﬁed H2O2-activated
myoglobin as the catalyst of this reaction, and 3-methoxyphthalic
acid, the ﬁnal product of DOX oxidative degradation (Figure 1)
was detected in hearts of mice exposed to DOX or human heart
stripes incubated with DOX (Menna et al., 2010). Importantly, 3-
methoxyphthalic acid proved to be much less toxic to cultured car-
diomyocytes and mice than equimolar amounts of DOX, possibly
because this metabolic pathway prevents quinone-semiquinone
redox cycling. These ﬁndings suggest that anthracycline oxidative
degradationmay represent a salvage pathway that diminishesDOX
cardiotoxicity (Menna et al., 2010).
IRON AND ANTHRACYCLINE CARDIOTOXICITY
The relative weight of each individual mechanism in the develop-
ment of anthracycline-induced cardiotoxicity is uncertain, but the
role of iron in DOX cardiotoxicity is widely recognized (Minotti
et al., 1999; Xu et al., 2005; Simu◦nek et al., 2009).
Perhaps the most compelling proof is provided by the effective-
ness of the iron chelator dexrazoxane at preventing cardiotoxicity,
both in animal and clinical studies. The use of dexrazoxane
in patients has been debated after reports showing myelotoxic-
ity and interference with anticancer effects of DOX, and others
FIGURE 1 | Structure and simplified scheme of molecular
transformations of Doxorubicin. Redox cycling between the quinone and
semiquinone forms (ring C) of Doxorubicin (DOX) leads to oxygen radicals
formation. The residue involved in DOXol formation following two-electron
reduction of the carbonyl group in ring A is marked in blue. Oxidative
pathways involving a hydroquinone-derived semiquinone lead to formation of
a diquinone (rings B and C), and eventual degradation of DOX with formation
of 3-methoxytphthalic acid as remnant of ring D.
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with opposite conclusions (discussed by Steˇrba et al., 2013).
Nevertheless, the observation that dexrazoxane protects cancer
patients against cardiotoxicity demonstrates that alterations in
iron homeostasis are involved in anthracycline-induced CHF.
Additional and complementary experimental evidence for the
role of iron in DOX cardiotoxicity was provided by studies show-
ing that iron overload increases the cardiotoxic effects of the
drug. Early studies showed that iron loading exacerbated DOX
toxicity in cell culture (Hershko et al., 1993; Link et al., 1996).
Moreover, increasing iron stores in rats by dietary iron load-
ing enhanced DOX cardiotoxicity (Panjrath et al., 2007), and mice
lacking HFE, a model that mimics the iron overload found in
human hereditary hemochromatosis, showed higher susceptibility
to DOX-dependent cardiac damage (Miranda et al., 2003). Impor-
tantly, a recent study showed that DOX-induced myocardial injury
was associated with the frequency of HFE gene mutations in sur-
vivors of childhood acute lymphoblastic leukemia (Lipshultz et al.,
2013b).
IRON-DEPENDENT MECHANISMS OF ANTHRACYCLINE
CARDIOTOXICITY
It is considered that by forming anthracycline-iron complexes iron
potentiates the toxicity of DOX-derived ROS transforming rela-
tively safe species like O2•− and H2O2 into the much more reactive
and toxic hydroxyl radical OH• or iron-peroxo complexes that
damage DNA, proteins, and lipids (Minotti et al., 1999; Xu et al.,
2005; Simu◦nek et al., 2009). Moreover, it has been proposed that
the redox cycling of the quinone moiety (Figure 1) would enable
anthracyclines to increase the cellular levels of iron by mobilizing
it from ferritin (see below), and thus amplify iron-mediated oxida-
tive stress. Indeed, several lines of evidence in preclinical models
indicated that iron and oxygen radicals conspire at inducing car-
diotoxicity. However, the so-called “ROS and iron hypothesis”
has been called into question; in fact, while iron chelators like
dexrazoxane mitigate anthracycline cardiotoxicity, none of several
antioxidants proved to be protective against chronic cardiotoxic-
ity in clinical settings (Minotti et al., 2004a; Octavia et al., 2012;
Steˇrba et al., 2013).
Accordingly, we showed that DOX doses lower than those usu-
ally adopted in experimental studies, but in the range of the plasma
levels found in patients undergoing slow infusion chemother-
apy induced apoptosis of cardiac-derived H9c2 myocytes in the
absence of ROS production, thus supporting the idea that oxida-
tive stress does not play a role in DOX-dependent apoptotic death
of cardiomyocytes (Bernuzzi et al., 2009).
We recently provided evidence suggesting an alternative mech-
anism at the basis of the protective capacity of iron chelators
against cardiotoxicity (Spagnuolo et al., 2011). Treatment with
dexrazoxane induced hypoxia inducible factor (HIF) in H9c2 car-
diomyocytes. Moreover, it prevented the activation of apoptosis
caused by treatment of H9c2 cells with low but pharmacologi-
cally relevant doses of DOX. The role of HIF was demonstrated
by experiments involving pharmacological or genetic manipula-
tion of HIF activity: the inhibition of HIF activity blunted the
protective effect of iron chelation. Conversely, overexpressing
HIF conferred protection from DOX-dependent cell death also
in the absence of dexrazoxane. HIF exerted its defensive effect
by activating the expression of protective proteins, as treatment
with the chelator induced the synthesis of anti-apoptotic proteins
known to be HIF targets.
These results suggest that the HIF pathway may contribute
to the cardioprotective effect of iron chelation. Moreover, these
results reinforce the idea that the protection against DOX toxicity
provided by the iron chelator may be ROS-independent.
EFFECT OF DOXORUBICIN ON PROTEINS OF IRON
METABOLISM
The data reported above, together with evidence discussed below,
indicate that the role of iron in DOX cardiotoxicity may be medi-
ated not by DOX–iron interactions, but by profound interference
with proteins involved in intracellular iron trafﬁc (Figure 2). This
concept is in agreement with the essential role of iron in regu-
lating fundamental cellular processes like DNA synthesis, energy
production, calcium channel function, redox balance, etc. (Hentze
et al., 2004).
IRON REGULATORY PROTEINS
The relationship between iron and anthracycline cardiotoxicity
may be related to disruption of cardiac iron homeostasis obtained
by means of targeted interaction of DOX with iron regulatory
proteins (IRP1 and IRP2), the key regulators of intracellular iron
metabolism (Cairo and Pietrangelo, 2000; Rouault, 2006; Cairo
and Recalcati, 2007; Muckenthaler et al., 2008). IRPs form the
FIGURE 2 | Interaction of DOX with proteins of iron metabolism.The
interaction of DOX with the functions of iron regulatory proteins (IRPs) and
ferritin (Ft) affects iron homeostasis and may lead to ROS-dependent and
independent damage and apoptotic cell death. Iron sequestration by the
iron chelator dexrazoxane (DRZ) or mitochondrial ferritin FtMt may prove
cardioprotective.
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basis of a homeostatic mechanism that optimizes the metabolic
utilization of iron while avoiding its involvement in potentially
toxic reactions. In mammalian cells, iron levels are ﬁnely con-
trolled by means of opposite but balanced regulation of ferritin,
the iron sequestering protein, and transferrin receptor (TfR1),
the major iron uptake protein (Cairo and Pietrangelo, 2000). The
post-transcriptional control of the cellular levels of ferritin and
TfR1 is exerted by IRP-1 and IRP-2, cytosolic proteins that bind
to iron regulatory elements (IRE) in ferritin and TfR1 mRNAs
(Recalcati et al., 2010). Under conditions of iron scarcity, bind-
ing of IRPs to IRE represses the translation of ferritin mRNAs
and at the same time enhances the half-life of TfR1 mRNA. This
results in increased iron availability for the requirements of the
cell. On the contrary, when iron is abundant, IRP activity is
decreased, and thereby ferritin mRNAs are translated whereas
TfR1 mRNA is degraded; hence, this mechanism facilitates iron
storage. It is noteworthy that IRPs can regulate mRNAs for other
proteins closely related to iron utilization (mitochondrial aconi-
tase and δ-aminolevulinic acid synthase), uptake (DMT1), and
release (ferroportin). Hence, their inﬂuence extends over a num-
ber of regulatory pathways controlling the iron status of the cell
(Cairo and Recalcati, 2007).
IRP1 is a bifunctional protein that is also able to act as an
aconitase, thus converting citrate to isocitrate, when it con-
tains a [4Fe–4S] cluster (i.e., in iron-rich cells). On the other
hand, when intracellular iron levels are low and the cluster is
not formed, IRP-1 becomes an RNA-binding protein. Switch-
ing between these two forms therefore represents a mechanism
allowing aconitase/IRP1 to adapt iron trafﬁcking to the cell
requirements. By providing isocitrate to isocitrate dehydrogenase,
IRP-1 may also control the cellular levels of NADH+ H+. IRP2,
which is similar to IRP1 but cannot assemble a [4Fe–4S] cluster,
is ubiquitinated and degraded by the proteasome in response to
iron, whereas it builds up in iron poor cells. IRP-2 degradation
also occurs following oxidative modiﬁcations induced by reac-
tive oxygen and nitrogen intermediates (Cairo and Pietrangelo,
2000; Rouault, 2006; Cairo and Recalcati, 2007; Muckenthaler
et al., 2008).
How DOX affects IRPs ? Pathways linking interactions of IRPs
with DOX, DOXol, and quinone-derived ROS, have been char-
acterized, and shown to play a role in cardiotoxicity (Cairo et al.,
2002). Observations conducted on cell-free systems or cardiac cell
lines have demonstrated that after interaction with DOXol IRP-1
ﬁrst looses the [4Fe–4S] cluster and then is converted by ROS into
a“null”protein lacking bothRNAbinding and enzymatic activities
(Minotti et al., 1998, 2001). Other studies provided data indicat-
ing a slightly different mechanism, by which such a “null” protein
would be formed by DOX–iron complexes (Kwok and Richard-
son, 2002). Moreover, ROS-mediated damage targets IRP-2 to
proteolysis (Minotti et al., 1998, 2001). The attack of DOX, and
in particular of its secondary alcohol metabolite, to IRPs may dys-
regulate iron homeostasis in the cell not only by disrupting IRP’s
regulatory function, but also through the release of iron atoms
from the Fe–S cluster of IRP1; this, rather than ferritin (see below),
may represent a source of iron that facilitates iron-mediated free
radical formation and apoptosis. The demonstration that anthra-
cyclines can interact with IRE regions of mRNAs (Canzoneri and
Oyelere, 2008), thus affecting IRP-mediated regulation of sev-
eral proteins of iron metabolism, has indicated another possible
pathway through which DOX can disrupt iron balance.
What could be the pathologic consequences of a DOX-
dependent inactivation of both IRPs? It should be kept in
mind that only mice lacking both IRPs are not viable; this
indicates that one IRP is sufﬁcient to maintain iron balance,
even though IRP-1-deﬁcient mice did not show any phenotype
whereas mice lacking IRP-2 have neurological and hematological
abnormalities (Recalcati et al., 2010). In addition to the prob-
lems related to the relative importance of each IRP, another
complicating factor comes from conﬂicting results obtained in
animal models. Studies in a rat model of chronic cardiotoxicity
found no evidence of impaired IRP-1 binding activity follow-
ing DOX administration (Cusack et al., 2006), but evidence of
IRP-1/aconitase sensitivity to DOX was obtained by other authors
(Sacco et al., 2003). On the other hand, studies exploiting IRP-
1-deﬁcient mice showed that an acute DOX treatment caused
cardiac damage irrespective of the presence or absence of IRP-1
(Corna et al., 2006).
Taking into consideration these inconsistencies, one should
appreciate the aforesaid pharmacokinetic and metabolic limita-
tions that restrict the validity of the preclinical models of DOX
cardiotoxicity. However, it could be concluded that, by allowing
ferritin mRNAs translation, an acute loss of IRP-2 might permit
free iron sequestration in newly formed ferritin shells before it
triggers oxidative damage. This effect would be consistent with
the protective effect of ferritin (see below). On the other hand,
a chronic loss of IRP-2 is expected to be more injurious, par-
ticularly in case IRP-1 is also irreversibly damaged. In fact, the
embryonic mortality of IRP-1 and IRP-2 double deﬁcient mice
anticipates that complete disruption of the IRP/IRE system is not
easily compensated.
FERRITIN
Another possible mechanism linking iron and anthracycline
metabolism involves ferritin. While in vitro experiments using
puriﬁed components suggested that the semiquinone free radi-
cal and O2•− produced by redox cycling of DOX quinone moiety
caused iron release from ferritin (Thomas andAust, 1986), the role
of ferritin in vivo seems quite opposite. In fact, recent data suggest
that the increase in ferritin synthesis induced by DOX could be
a defensive mechanism to limit the amount of iron available for
ROS production in the heart, and thus prevent oxidative injury,
in line with the known antioxidant function of this protein (Cairo
et al., 1995; Arosio and Levi, 2010). We demonstrated that fer-
ritin is induced in H9c2 cardiomyocytes (Corna et al., 2004) and
mouse hearts (Corna et al., 2006) exposed to DOX and protected
the cells against iron toxicity. Newly formed ferritin can there-
fore sequester iron and may paradoxically represent a defense
for cardiomyocytes. These ﬁndings were recently supported by
two studies demonstrating that NF-kB-mediated ferritin H chain
induction plays an important role in the mitochondrial protec-
tion offered by metformin against DOX cardiotoxicity in isolated
cardiomyocytes (Asensio-López et al., 2013a,b). Moreover, it has
been shown that exposure of cardiomyocytes to DOX leads to
higher accumulation of iron into ferritin by mechanisms that
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impair iron release from ferritin and/or lysosomal/proteasomal
degradation of this iron-storage protein (Kwok and Richardson,
2003, 2004).
As reported above, a number of observations indicate that
cardiac mitochondria are preferential targets of anthracyclines.
Additional evidence was recently provided by data showing that
the anthracycline epirubicin has an intracellular distribution dif-
ferent from that of DOX: it accumulates in acidic organelles
(lysosomes, recycling endosomes) and spares the mitochondria
(Salvatorelli et al., 2006). This appears to be one of the reasons for
the reduced cardiotoxicity of this analog.
In this context, recent results point to a critical role for mecha-
nisms controlling mitochondrial iron availability in anthracycline
cardiotoxicity. In particular, it has been recently shown that
exposure to DOX induces iron accumulation speciﬁcally in mito-
chondria, and mice with heart-speciﬁc deletion of ABCB8, which
is involved in iron export out of the mitochondria, were more
sensitive to DOX cardiotoxicity, whereas the opposite effect was
obtainedwithABCB8overexpression (Ichikawa et al., 2014). Mito-
chondrial ferritin (FtMt), which is a recently identiﬁed ferritin
type that accumulates speciﬁcally in the mitochondria where read-
ily accumulates iron (Arosio and Levi, 2010), may be another
key player. FtMt expression, which is not controlled by intra-
cellular iron levels, is high in mitochondria-rich tissues, such as
the testis, brain, heart. Despite the lack of evident phenotype
in FtMt-deﬁcient mice (Bartnikas et al., 2010), studies in cul-
tured cells overexpressing FtMt showed that, by sequestering iron
inside the mitochondria, FtMt is able to reduce iron-mediated
oxidative damage (Campanella et al., 2009). Moreover, it has
been recently demonstrated that ectopic expression of FtMt in
HeLa cells was able to reduce DOX-mediated cytotoxicity (Cocco
et al., 2013). Although this effect was not obtained in cardiac
cells, these results strongly suggested that FtMt may play a rel-
evant role in DOX cardiotoxicity. Indeed, FtMt induction was
recently found in the heart of DOX-treated mice (Ichikawa et al.,
2014).
Given the role of mitochondria in cellular iron homeostasis,
their importance as producers and targets of ROS, and their inter-
action with anthracyclines, further investigation of the effects of
DOX on mitochondrial iron metabolism is required to increase
our knowledge of DOX cardiotoxicity.
CONCLUSIONS AND PERSPECTIVES
Understanding the molecular basis of cardiotoxicity is impor-
tant to improve the therapeutic use of anthracyclines, which still
remain among the most effective antitumor drugs, and to iden-
tify less cardiotoxic analogs. In this context, the role of iron in
the pathogenesis of cardiac damage is undisputed, but the precise
molecular mechanisms underlying its effects remain incompletely
understood (Figure 2). While early studies pointed to a role as
ampliﬁer of the free radical generation initiated by DOX redox
cycling, more recent evidence suggests that the cardiotoxic role of
iron should not be restricted to the oxidative stress scenario. The
fact that anthracycline cardiotoxicity is mitigated by iron chela-
tors but not by antioxidants, together with biochemical evidence
showing that proteins important for cellular iron homeostasis are
speciﬁcally targeted byDOX, indicates that iron and anthracyclines
can also induce oxidant-independent cell injury. Exploring more
deeply the role of iron in the pathogenic mechanisms of DOX
cardiotoxicity will reveal useful insights for the development of
improved therapeutic strategies against anthracycline-dependent
heart damage and CHF.
ACKNOWLEDGMENTS
This work was supported by grants from Ministero dell’Istruzione,
dell’Università e della Ricerca, and Ministero della Salute.
REFERENCES
Armenian, S. H., Ding, Y., Mills, G., Sun, C., Venkataraman, K., Wong, F. L., et al.
(2013). Genetic susceptibility to anthracycline-related congestive heart failure in
survivors of haematopoietic cell transplantation. Br. J. Haematol. 163, 205–213.
doi: 10.1111/bjh.12516
Arosio, P., andLevi, S. (2010). Cytosolic andmitochondrial ferritins in the regulation
of cellular iron homeostasis and oxidative damage. Biochim. Biophys. Acta 1800,
783–792. doi: 10.1016/j.bbagen.2010.02.005
Asensio-López, M. C., Sanchez-Mas, J., Pascual-Figal, D. A., De Torre, C.,
Valdes, M., and Lax, A. (2013a). Ferritin heavy chain as main mediator
of preventive effect of metformin against mitochondrial damage induced by
doxorubicin in cardiomyocytes. Free Radic. Biol. Med. 67C, 19–29. doi:
10.1016/j.freeradbiomed.2013.11.003
Asensio-López, M. C., Sánchez-Más, J., Pascual-Figal, D. A., Abenza, S., Pérez-
Martínez, M. T., Valdés, M., et al. (2013b). Involvement of ferritin heavy chain
in the preventive effect of metformin against doxorubicin-induced cardiotox-
icity. Free Radic. Biol. Med. 57, 188–200. doi: 10.1016/j.freeradbiomed.2012.
09.009
Bartnikas, T. B., Campagna, D. R., Antiochos, B., Mulhern, H., Pondarré, C., and
Fleming,M. D. (2010). Characterization of mitochondrial ferritin-deﬁcient mice.
Am. J. Hematol. 85, 958–960. doi: 10.1002/ajh.21872
Bernuzzi, F., Recalcati, S., Alberghini, A., and Cairo, G. (2009). Reactive oxygen
species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role
for heme oxygenase-1 down-modulation. Chem. Biol. Interact. 177, 12–20. doi:
10.1016/j.cbi.2008.09.012
Berthiaume, J. M., and Wallace, K. B. (2007). Adriamycin-induced oxidative
mitochondrial cardiotoxicity. Cell Biol. Toxicol. 23, 15–25. doi: 10.1007/s10565-
006-0140-y
Blanco, J. G., Leisenring, W. M., Gonzalez-Covarrubias, V. M., Kawashima, T. I.,
Davies, S. M., Relling, M.V., et al. (2008). Genetic polymorphisms in the carbonyl
reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1
in patients who developed anthracycline-related congestive heart failure after
childhood cancer. Cancer 112, 2789–2795. doi: 10.1002/cncr.23534
Cairo, G., and Pietrangelo, A. (2000). Iron regulatory proteins in pathobiology.
Biochem. J. 352(Pt 2), 241–250. doi: 10.1042/0264-6021:3520241
Cairo, G., and Recalcati, S. (2007). Iron-regulatory proteins: molecular biol-
ogy and pathophysiological implications. Expert Rev. Mol. Med. 9, 1–13. doi:
10.1017/S1462399407000531
Cairo, G., Recalcati, S., Pietrangelo, A., and Minotti, G. (2002). The iron regulatory
proteins: targets and modulators of free radical reactions and oxidative damage.
Free Radic. Biol. Med. 32, 1237–1243. doi: 10.1016/S0891-5849(02)00825-0
Cairo, G., Tacchini, L., Pogliaghi, G., Anzon, E., Tomasi, A., and Bernelli-Zazzera,
A. (1995). Induction of ferritin synthesis by oxidative stress. Transcriptional and
post-transcriptional regulation by expansion of the“free” iron pool. J. Biol. Chem.
270, 700–703. doi: 10.1074/jbc.270.2.700
Campanella, A., Rovelli, E., Santambrogio, P., Cozzi, A., Taroni, F., and Levi, S.
(2009). Mitochondrial ferritin limits oxidative damage regulating mitochondrial
iron availability: hypothesis for a protective role in Friedreich ataxia. Hum. Mol.
Genet. 18, 1–11. doi: 10.1093/hmg/ddn308
Canzoneri, J. C., and Oyelere, A. K. (2008). Interaction of anthracyclines with
iron responsive element mRNAs. Nucleic Acids Res. 36, 6825–6834. doi:
10.1093/nar/gkn774
Carvalho, F. S., Burgeiro,A.,Garcia, R.,Moreno,A. J., Carvalho,R.A., andOliveira, P.
J. (2014). Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell
death to cardiomyopathy. Med. Res. Rev. 34, 106–135. doi: 10.1002/med.21280
Cocco, E., Porrini, V., Derosas, M., Nardi, V., Biasiotto, G., Maccarinelli, F., et al.
(2013). Protective effect of mitochondrial ferritin on cytosolic iron dysregulation
www.frontiersin.org February 2014 | Volume 5 | Article 25 | 5
Gammella et al. Iron and anthracycline cardiotoxicity
induced by doxorubicin in HeLa cells. Mol. Biol. Rep. 40, 6757–6764. doi:
10.1007/s11033-013-2792-z
Corna, G., Galy, B., Hentze, M. W., and Cairo, G. (2006). IRP1-independent alter-
ations of cardiac iron metabolism in doxorubicin-treated mice. J. Mol. Med.
(Berl.) 84, 551–560. doi: 10.1007/s00109-006-0068-y
Corna, G., Santambrogio, P., Minotti, G., and Cairo, G. (2004). Doxorubicin
paradoxically protects cardiomyocytes against iron-mediated toxicity: role of
reactive oxygen species and ferritin. J. Biol. Chem. 279, 13738–13745. doi:
10.1074/jbc.M310106200
Cusack, B. J., Gambliel, H., Musser, B., Hadjokas, N., Shadle, S. E., Charlier, H., et al.
(2006). Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344
rat by dexrazoxane and effects on ironmetabolism. CancerChemother. Pharmacol.
58, 517–526. doi: 10.1007/s00280-006-0199-4
Fogli, S., Nieri, P., and Breschi,M. C. (2004). The role of nitric oxide in anthracycline
toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB
J. 18, 664–675. doi: 10.1096/fj.03-0724rev
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., and Sawyer,
D. B. (2008). Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol.
26, 3777–3784. doi: 10.1200/JCO.2007.14.9401
Hentze, M. W., Muckenthaler, M. U., and Andrews, N. C. (2004). Balancing
acts: molecular control of mammalian iron metabolism. Cell 117, 285–297. doi:
10.1016/S0092-8674(04)00343-5
Hershko, C., Link, G., Tzahor, M., Kaltwasser, J. P., Athias, P., Grynberg, A.,
et al. (1993). Anthracycline toxicity is potentiated by iron and inhibited by
deferoxamine: studies in rat heart cells in culture. J. Lab. Clin. Med. 122, 245–251.
Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Naga Prasad, S. V.,
et al. (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial
iron accumulation. J. Clin. Invest. 124, 617–630. doi: 10.1172/JCI72931
Kwok, J. C., and Richardson, D. R. (2002). Unexpected anthracycline-mediated
alterations in iron-regulatory protein–RNA-binding activity: the iron and copper
complexes of anthracyclines decrease RNA-binding activity. Mol. Pharmacol. 62,
888–900. doi: 10.1124/mol.62.4.888
Kwok, J. C., and Richardson, D. R. (2003). Anthracyclines induce accumulation of
iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron
mobilization pathway. Mol. Pharmacol. 63, 849–861. doi: 10.1124/mol.63.4.849
Kwok, J. C., and Richardson, D. R. (2004). Examination of the mechanism(s)
involved in doxorubicin-mediated iron accumulation in ferritin: studies using
metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents.
Mol. Pharmacol. 65, 181–195. doi: 10.1124/mol.65.1.181
Link, G., Tirosh, R., Pinson, A., and Hershko, C. (1996). Role of iron in the poten-
tiation of anthracycline cardiotoxicity: identiﬁcation of heart cell mitochondria
as a major site of iron–anthracycline interaction. J. Lab. Clin. Med. 127, 272–278.
doi: 10.1016/S0022-2143(96)90095-5
Lipshultz, S. E., Cochran, T. R., Franco, V. I., and Miller, T. L. (2013a). Treatment-
related cardiotoxicity in survivors of childhood cancer. Nat. Rev. Clin. Oncol. 10,
697–710. doi: 10.1038/nrclinonc.2013.195
Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T. L., Colan, S. D., Neuberg, D.
S., et al. (2013b). Impact of hemochromatosis gene mutations on cardiac status
in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 119,
3555–3562. doi: 10.1002/cncr.28256
Menna, P., Salvatorelli, E., and Minotti, G. (2010). Anthracycline degradation in
cardiomyocytes: a journey to oxidative survival. Chem. Res. Toxicol. 23, 6–10. doi:
10.1021/tx9003424
Minotti, G., Cairo, G., and Monti, E. (1999). Role of iron in anthracycline
cardiotoxicity: new tunes for an old song? FASEB J. 13, 199–212.
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004a). Anthra-
cyclines: molecular advances and pharmacologic developments in antitumor
activity and cardiotoxicity. Pharmacol. Rev. 56, 185–229. doi: 10.1124/pr.56.2.6
Minotti,G., Recalcati, S.,Menna, P., Salvatorelli, E.,Corna,G., andCairo,G. (2004b).
Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-
dependent and independent mechanisms. Methods Enzymol. 378, 340–361. doi:
10.1016/S0076-6879(04)78025-8
Minotti, G., Recalcati, S., Mordente, A., Liberi, G., Calaﬁore, A. M., Mancuso,
C., et al. (1998). The secondary alcohol metabolite of doxorubicin irreversibly
inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human
myocardium. FASEB J. 12, 541–552.
Minotti, G., Ronchi, R., Salvatorelli, E., Menna, P., and Cairo, G. (2001). Doxoru-
bicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes:
evidence for distinct metabolic pathways and implications for iron-mediated
cardiotoxicity of antitumor therapy. Cancer Res. 61, 8422–8428.
Miranda, C. J., Makui, H., Soares, R. J., Bilodeau, M., Mui, J., Vali, H., et al.
(2003). Hfe deﬁciency increases susceptibility to cardiotoxicity and exacerbates
changes in iron metabolism induced by doxorubicin. Blood 102, 2574–2580. doi:
10.1182/blood-2003-03-0869
Muckenthaler, M. U., Galy, B., and Hentze, M. W. (2008). Systemic
iron homeostasis and the iron-responsive element/iron-regulatory protein
(IRE/IRP) regulatory network. Annu. Rev. Nutr. 28, 197–213. doi:
10.1146/annurev.nutr.28.061807.155521
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., and
Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: from molecular
mechanisms to therapeutic strategies. J. Mol. Cell Cardiol. 52, 1213–1225. doi:
10.1016/j.yjmcc.2012.03.006
Panjrath, G. S., Patel, V., Valdiviezo, C. I., Narula, N., Narula, J., and Jain, D. (2007).
Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J.
Am. Coll. Cardiol. 49, 2457–2464. doi: 10.1016/j.jacc.2007.02.060
Recalcati, S., Minotti, G., and Cairo, G. (2010). Iron regulatory proteins: from
molecular mechanisms to drug development. Antioxid. Redox. Signal. 13, 1593–
1616. doi: 10.1089/ars.2009.2983
Rouault, T. A. (2006). The role of iron regulatory proteins in mammalian iron
homeostasis and disease. Nat. Chem. Biol. 2, 406–414. doi: 10.1038/nchembio807
Sacco, G., Giampietro, R., Salvatorelli, E., Menna, P., Bertani, N., Graiani, G.,
et al. (2003). Chronic cardiotoxicity of anticancer anthracyclines in the rat: role
of secondary metabolites and reduced toxicity by a novel anthracycline with
impaired metabolite formation and reactivity. Br. J. Pharmacol. 139, 641–651.
doi: 10.1038/sj.bjp.0705270
Salvatorelli, E., Guarnieri, S., Menna, P., Liberi, G., Calaﬁore, A. M., Mariggiò, M. A.,
et al. (2006). Defective one- or two-electron reduction of the anticancer anthra-
cycline epirubicin in human heart. Relative importance of vesicular sequestration
and impaired efﬁciency of electron addition. J. Biol. Chem. 281, 10990–11001.
doi: 10.1074/jbc.M508343200
Simu◦nek, T., Stérba, M., Popelová, O., Adamcová, M., Hrdina, R., and Gersl, V.
(2009). Anthracycline-induced cardiotoxicity: overview of studies examining the
roles of oxidative stress and free cellular iron. Pharmacol. Rep. 61, 154–171.
Spagnuolo, R. D., Recalcati, S., Tacchini, L., and Cairo, G. (2011). Role of
hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomy-
ocytes from doxorubicin-induced toxicity. Br. J. Pharmacol. 163, 299–312. doi:
10.1111/j.1476-5381.2011.01208.x
Steˇrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovarˇíková, P., Geršl, V., et al.
(2013). Oxidative stress, redox signaling, and metal chelation in anthracycline
cardiotoxicity and pharmacological cardioprotection. Antioxid. Redox. Signal. 18,
899–929. doi: 10.1089/ars.2012.4795
Thomas, C. E., and Aust, S. D. (1986). Reductive release of iron from ferritin
by cation free radicals of paraquat and other bipyridyls. J. Biol. Chem. 261,
13064–13070.
Xu, X., Persson, H. L., and Richardson, D. R. (2005). Molecular pharmacology of
the interaction of anthracyclines with iron. Mol. Pharmacol. 68, 261–271.
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., et al. (2012).
Identiﬁcation of the molecular basis of doxorubicin-induced cardiotoxicity. Nat.
Med. 18, 1639–1642. doi: 10.1038/nm.2919
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 23 January 2014; paper pending published: 29 January 2014; accepted: 12
February 2014; published online: 26 February 2014.
Citation: Gammella E, Maccarinelli F, Buratti P, Recalcati S and Cairo G (2014)
The role of iron in anthracycline cardiotoxicity. Front. Pharmacol. 5:25. doi:
10.3389/fphar.2014.00025
This article was submitted to Drug Metabolism and Transport, a section of the journal
Frontiers in Pharmacology.
Copyright © 2014 Gammella, Maccarinelli, Buratti, Recalcati and Cairo. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | Drug Metabolism andTransport February 2014 | Volume 5 | Article 25 | 6
